Standard BioTools to merge with Treeline Biosciences in all-stock deal; LAB stockholders to own ~16%

STANDARD BIOTOOLS INC.

All-stock merger; Treeline valued at $2.5B, Standard BioTools at ~$460M; combined co. to be named Treeline Biosciences Holdings.
Former LAB stockholders to hold ~16% of combined co., Treeline stockholders ~84%; closing expected H2 2026.
Legacy mass cytometry/microfluidics business to be sold or wound down; CVRs issued to LAB stockholders for proceeds.
Treeline CEO Josh Bilenker to lead combined co.; board to have 12 members, 10 from Treeline, 2 from LAB.
Voting agreements covering ~39% of LAB shares; termination fee of $16.1M payable by LAB in certain circumstances.

item 1.01 item 3.02 item 5.01 item 5.02 item 7.01 item 9.01

Featured in Daily 8-K Digest

Selected #5 for 2026-06-08. Read digest

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

STANDARD BIOTOOLS INC. entered into Agreement and Plan of Merger and Reorganization with Treeline Biosciences, Inc. (effective 2026-06-06).

Action: entry
Agreement: merger
Counterparty: Treeline Biosciences, Inc.
Effective: 2026-06-06

Exact text from the filing

Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Treeline Biosciences, Inc., a Delaware corporation (“Treeline”), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (“Merger Sub”)

View on SEC.gov

745 material agreements filed in the last 30 days. Browse all material agreements →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-071195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.